CLOs on the Move

Mersana

www.mersana.com

 
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mersana.com
  • 840 Memorial Drive
    Cambridge, MA USA 02139
  • Phone: 617.498.0020

Executives

Name Title Contact Details
Chuck Miller
 Senior Vice President of Regulatory Affairs Profile
Alejandra Carvajal
 Senior Vice President and Chief Legal Officer Profile

Similar Companies

The Coding Source LLC

The Coding Source LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.

GenBio

GenBio is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Willow Industries

Willow Industries Ozone Systems. Mitigate Mold & Bacteria. Willow systems provide clean and effective solutions to cannabis contamination.

Xilio Therapeutics

Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.